Drug Profile
Research programme: artificial intelligence aided therapeutics - Recursion Pharmaceuticals
Alternative Names: Inborn genetic disorder therapeutics - Recursion Pharmaceuticals; REC-0000355; REC-0000382; REC-0000716; REC-0001117; REC-0001202; REC-0001317; REC-0001571; REC-0001982Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Recursion Pharmaceuticals
- Class Anti-inflammatories; Antibacterials; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Charcot-Marie-Tooth disease; Clostridium difficile infections; Haematological disorders; Inborn error metabolic disorders; Inflammation; Neurological disorders; Neuronal ceroid lipofuscinosis; Skin disorders
- Research Eye disorders
- No development reported Cardiovascular disorders; Neurofibromatosis 2
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Neurofibromatosis-2 in USA
- 04 Mar 2020 Early research in Eye disorders in USA (unspecified route) Before March 2020 (Recursion pharma pipeline March 2020)